Cipla News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Cipla Ltd.

09 Jan 2026

1448.30

-1.15%

Earnings Call

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Pursuant to Regulation 30 of Securities and Exchange Baord of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 23rd January, 2026.

pdf

Cipla Ltd.

08 Jan 2026

1448.30

-1.15%

Cipla among 5 F&O stocks with a sharp rise in futures open interest

Economic Times

On January 7, futures open interest rose notably across five F&O stocks, contributing to a cumulative increase of over 10% compared with the previous session. A rise in futures open interest points to a build-up of active contracts, suggesting fresh positioning or expansion of existing positions by traders.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

07 Jan 2026

1448.30

-1.15%

Company Update

Cipla Ltd - 500087 - Reply On Clarification Sought By Exchange

BSE India

Reply on clarification sought by Exchange

pdf

Cipla Ltd.

07 Jan 2026

1448.30

-1.15%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30(11) Of The SEBI (Listing Obligations And Disclosure …

BSE India

News clarification enclosed

pdf

Cipla Ltd.

07 Jan 2026

1448.30

-1.15%

Company Update

Cipla Ltd - 500087 - Clarification sought from Cipla Ltd

BSE India

The Exchange has sought clarification from Cipla Ltd on January 07, 2026, with reference to news appeared in https://www.moneycontrol.com/ dated January 07, 2026 quoting "Cipla shares slide 4.5% after USFDA flags compliance gaps at key Lanreotide supplier site" The reply is awaited.

Cipla Ltd.

07 Jan 2026

1448.30

-1.15%

Cipla Shares Fall 4% After USFDA Flags Compliance Issues At Pharmathen's Rodopi Facility

NDTV Profit

The form includes nine observations highlighting serious concerns over current Good Manufacturing Practices (cGMP).

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla Ltd.

30 Dec 2025

1448.30

-1.15%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Superannuation of Senior Management Personnel on 31st December 2025

pdf

Cipla Ltd.

23 Dec 2025

1448.30

-1.15%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for Meeting Of The Board Of Directors Of …

BSE India

Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2025.

pdf

Cipla Ltd.

23 Dec 2025

1448.30

-1.15%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...